Multicenter study of pegylated liposomal doxorubicin in patients with cutaneous T-cell lymphoma

Cancer

Volumn 98, Issue 5, 2003, Pages 993-1001

  Wollina, Uwe ^a   Dummer, Reinhard ^b   Brockmeyer, Norbert H ^c   Konrad, Helga ^a   Busch, J O ^d   Kaatz, Martin ^e   Knopf, Burkhard ^f   Koch, Hans Jürgen ^g   Hauschild, Axel ^d  

^a ACADEMIC TEACHING HOSPITAL DRESDEN FRIEDRICHSTADT   (Germany)

^b UNIVERSITY OF ZURICH   (Switzerland)

^c RUHR UNIVERSITY BOCHUM   (Germany)

^d UNIVERSITY HOSPITAL SCHLESWIG HOLSTEIN   (Germany)

^e FRIEDRICH SCHILLER UNIVERSITY JENA   (Germany)

^f Heinrich Braun Klinikum   (Germany)

^g Department of Dermatology   (Germany)

Author keywords

Cutaneous T cell lymphoma; Doxorubicin; Liposomal drug formulation; Multicenter study; Pegylation

Indexed keywords

CYCLOPHOSPHAMIDE; DOXORUBICIN; FLUDARABINE; INTERFERON; LIPOSOME; METHOTREXATE; METHOXSALEN; PREDNISONE; UNCLASSIFIED DRUG; VINCRISTINE;

ADULT; AGED; ALOPECIA; ANEMIA; ANGINA PECTORIS; ARTICLE; BLOOD TOXICITY; CANCER CHEMOTHERAPY; CANCER RADIOTHERAPY; CANCER SURVIVAL; CAPILLARY LEAK SYNDROME; CENTRAL NERVOUS SYSTEM DISEASE; CHEMOTHERAPY INDUCED EMESIS; CLINICAL ARTICLE; CONSTIPATION; DIARRHEA; DRUG EFFICACY; DRUG ERUPTION; DRUG FORMULATION; DRUG SAFETY; DRUG TOLERABILITY; EDEMA; FEMALE; HUMAN; INTERTRIGO; LEUKOPENIA; LIVER TOXICITY; LYMPHOCYTOPENIA; MALE; MONOTHERAPY; MUCINOSIS; MULTICENTER STUDY; MYCOSIS FUNGOIDES; NAUSEA; PARTIAL THROMBOPLASTIN TIME; PHOTOCHEMOTHERAPY; PRIORITY JOURNAL; PUVA; RETROSPECTIVE STUDY; SIDE EFFECT; SKIN TOXICITY; STOMATITIS; T CELL LYMPHOMA; THROMBOCYTOPENIA; TREATMENT OUTCOME; WEIGHT GAIN;

ADULT; AGED; AGED, 80 AND OVER; ANTINEOPLASTIC AGENTS; DISEASE-FREE SURVIVAL; DOXORUBICIN; FEMALE; HUMANS; LIPOSOMES; LYMPHOMA, T-CELL, CUTANEOUS; MALE; MIDDLE AGED; RETROSPECTIVE STUDIES; TREATMENT OUTCOME;

EID: 0042388408     PISSN: 0008543X     EISSN: None     Source Type: Journal    
DOI: 10.1002/cncr.11593     Document Type: Article

References (40)

1. Kleinhans M, Tun-Kyi A, Gilliet M, et al. Functional expression of the eotaxin receptor CCR3 in CD30 positive cutaneous T-cell lymphoma. Blood. 2003;101:1487-1493.
2. Dummer R. CTCL - a tumour of skin homing T-cells. Exp Dermatol. 2002;11:483-484.
3. Wollina U, Graefe T, Feldrappe S, et al. Galectin fingerprinting by immuno- and lectin histochemistry in cutaneous lymphoma. J Cancer Res Clin Oncol. 2002;128:103-110.
4. Willemze R, Kerl H, Sterry W, et al. EORTC classification for primary cutaneous lymphomas. A proposal from the Cutaneous Lymphoma Study Group of the European Organization for Research and Treatment of Cancer. Blood. 1997;90:354-371.
5. Diamandidou E, Cohen PR, Kurzrock R. Mycosis fungoides and Sèzary syndrome. Blood. 1996;88:2385-2409.
6. Van Doorn R, Van Haselen CW, van Voorst Vader PC, et al. Mycosis fungoides: disease evolution and prognosis of 309 Dutch patients. Arch Dermatol. 2000;136:504-510.
7. Bunn PA Jr., Hoffmann SJ, Norris D, Golitz LE, Aeling JL. Systemic therapy of cutaneous T-cell lymphomas (mycosis fungoides and the Sèzary syndrome). Ann Intern Med. 1994;121:592-602.
8. Hortobágyi GN. Anthracyclines in the treatment of cancer. An overview, Drugs. 1997;54(Suppl 4):1-7.
9. Nair R, Ramakrishnan G, Nair NN, et al. A randomized comparison of the efficacy and toxicity of epirubicin and doxorubicin in the treatment of patients with non-Hodgkin's lymphomas. Cancer. 1998;82:2282-2288.
10. Tirelli U, Errante D, Van Glabbeke M, et al. CHOP is the standard regimen in patients > or = 70 years of age with intermediate-grade and high-grade non-Hodgkin's lymphoma: results of a randomized study of the European Organization for Research and Treatment of Cancer Lymphoma Cooperative Study Group. J Clin Oncol. 1998;16:27-34.
11. Crawford J. Clinical uses of pegylated pharmaceuticals in oncology. Cancer Treat Rev. 2002;28(Suppl A):7-11.
12. Wollina U, Graefe T, Karte K. Treatment of relapsing or recalcitrant cutaneous T-cell lymphoma with pegylated liposomal doxorubicin. J Am Acad Dermatol. 2000;42:40-46.
13. Wollina U, Graefe T, Kaatz M. Pegylated doxorubicin for primary cutaneous T-cell lymphoma: a report on ten patients with follow-up. J Cancer Res Clin Oncol. 2001;127:128-134.
14. Tsatalas C, Martinis G, Margaritis D, et al. Long-term remission of recalcitrant tumour-stage mycosis fungoides following chemotherapy with pegylated liposomal doxorubicin. J Eur Acad Dermatol Venereol. 2003;17:80-82.
15. EEC. Good clinical practice for trials on medicinal products in the European Community. 11/3976/88-EN. Brussels: European Commission, 1991.
16. Vonderheit EC, Bernengo MG, Burg G, et al. Update on erythrodermic cutaneous T-cell lymphoma: report of the International Society for Cutaneous Lymphomas. J Am Acad Dermatol. 2002;46:95-106.
17. Kerl H, Sterry W. Classification and staging. In: Burg G, Sterry W, editors. EORTC/BMFT Cutaneous Lymphoma Project Group: recommendations for staging and therapy of cutaneous lymphomas. Berlin: Springer, 1987:1-10.
18. Cheson BD, Horning SJ, Coiffier B, et al. Report of an International Workshop to Standardize Response Criteria for non-Hodgkin's lymphomas. J Clin Oncol. 1999;17:1244-1253.
19. Seegenschmiedt MH. Interdisciplinary documentation of treatment side effects in oncology. Present status and perspectives. Strahlenther Onkol. 1998;174(Suppl 3):25-29.
20. Lotem M, Hubert A, Lyass O, et al. Skin toxic effects of polyethylene glycol-coated liposomal doxorubicin. Arch Dermatol. 2000;136:1475-1480.
21. Alberts DS, Garcia DJ. Safety aspects of pegylated liposomal doxorubicin in patients with cancer. Drugs. 1997;54(Suppl 4):30-35.
22. 2. Ann Oncol. 2000;11:1029-1033.
23. Lorincz A. Cutaneous T-cell lymphoma (mycosis fungoides). Lancet. 1996;347:871-876.
24. Fierro MT, Quaglino P, Savoia P, Verrone A, Bernengo MG. Systemic polychemotherapy in the treatment of primary cutaneous lymphomas: a clinical follow-up study of 81 patients treated with COP or CHOP. Leuk Lymphoma. 1998;31:583-588.
25. Duvic M, Hester JP, Lemak NA. Photopheresis therapy for cutaneous T-cell lymphoma. J Am Acad Dermatol. 1996;35:573-579.
26. Akpek G, Koh HK, Bogen S, O'Hara C, Foss FM. Chemotherapy with etoposide, vincristine, doxorubicin, bolus cyclophosphamide, and oral prednisone in patients with refractory cutaneous T-cell lymphoma. Cancer. 1999;86:1368-1376.
27. Ho AD, Suciu S, Stryckmans P, et al. Pentostatin (Nipent) in T-cell malignancies. Leukemia Cooperative Group and the European Organization for Research and Treatment of Cancer. Semin Oncol. 2000;27(Suppl 5):52-57.
28. Kurzrock R, Pilat S, Duvic M. Pentostatin therapy of T-cell lymphomas with cutaneous manifestation. J Clin Oncol. 1999;17:3117-3121.
29. Dearden C, Matutes E, Catovsky D. Pentostatin treatment of cutaneous T-cell lymphoma. Oncology (Huntington). 2000;14(Suppl 2):37-40.
30. Zinzani PL, Baliva G, Magagnoli M, et al. Gemcitabine treatment in pretreated cutaneous T-cell lymphoma: experience in 44 patients. J Clin Oncol. 2000;18:2603-2606.
31. Duvic M, Martin AG, Kim Y, et al. Phase 2 and 3 clinical trial of oral bexarotene (Tagretin capsules) for the treatment of refractory or persistent early-stage cutaneous T-cell lymphoma. Arch Dermatol. 2001;137:649-652.
32. Duvic M, Hymes K, Heald P, et al. Bexarotene is effective and safe for treatment of refractory advanced-stage cutaneous T-cell lymphoma: multinational Phase II-III trial results. J Clin Oncol. 2001;19:2456-2471.
33. Waterhouse DN, Tardi PG, Mayer LD, Bally MP. A comparison of liposomal formulations of doxorubicin with drug administered in free form: changing toxicity profiles. Drug Safety. 2001;24:903-920.
34. Working PK, Dayan AD. Pharmacological - toxicological expert report: Caelyx® (Stealth® liposomal doxorubicin HCl). Hum Exp Toxicol. 1996;15:752-785.
35. Stewart JSW, Jablonowski H, Goebel F-D, et al. Randomised comparative trial of pegylated liposomal doxorubicin versus bleomycin and vincristine in the treatment of AIDS-related Kaposi's sarcoma. International Pegylated Liposomal Doxorubicin Study Group. J Clin Oncol. 1998;16:683-691.
36. Muggia FM. Clinical efficacy and prospects for use of pegylated liposomal doxorubicin in the treatment of ovarian and breast cancers. Drugs. 1997;54(Suppl 4):22-29.
37. Madhavan S, Northfelt DW. Lack of vesicant injury following extravasation of liposomal doxorubicin. J Natl Cancer Inst. 1995;87:1556-1557.
38. Gordon KB, Tajuddin A, Guitart J, Kuzel TM, Eramo LR, von Roenn J. Hand-foot syndrome associated with liposome-encapsulated doxorubicin therapy. Cancer. 1995;75:2169-2173.
39. Vail DM, Chun R, Thamm DH, Garrett LD, Cooley AJ, Obradovich JE. Efficacy of pyridoxine to ameliorate the cutaneous toxicity associated with doxorubicin containing pegylated (Stealth) liposomes: a randomized, double-blind clinical trial using a canine model. Clin Cancer Res. 1998;4:1567-1571.
40. Lopez AM, Wallace L, Dorr RT, Koff M, Hersh EM, Alberts DS. Topical DMSO treatment for pegylated liposomal doxorubicin-induced palmar-plantar erythrodysesthesia. Cancer Chemother Pharmacol. 1999;44:303-306.